CDK Inhibition May Overcome Mechanisms of Olaparib Resistance in Prostate Cancer
September 15th 2021By studying olaparib-sensitive and -resistant cell lines, researchers were able to gather insights regarding PARP inhibitor treatment and resistance mechanisms, including the use of CDK inhibition as a potential means of overcoming PARP inhibitor resistance in prostate cancer.
Olaparib Maintains Benefit Over Enzalutamide or Abiraterone in mCRPC
September 14th 2021Olaparib was still found to produce greater clinical benefit than enzalutamide or abiraterone acetate in patients with metastatic castration-resistant prostate cancer when the novel hormonal agents were examined separately rather than combined.
Adjuvant Pembrolizumab Continues to Uphold DFS Benefit Across RCC Subgroups
Pembrolizumab as an adjuvant therapy compared with placebo continued to showcase an impressive disease-free survival benefit in patients with clear cell renal cell carcinoma following nephrectomy, with improvement observed across subgroups.
LSAM-DTX Effective and Safe in NMIBC Using Direct, Multifaceted Approach
Large surface area microparticle docetaxel administered via direct intramural injection and intravesical instillations was found to be safe and showed preliminary signs of efficacy in patients with high-risk non-muscle invasive bladder cancer.
UGN-101 Induction Produces Durable Responses in Low-Grade Upper Tract Urothelial Carcinoma
Treatment with the mitomycin-containing reverse thermal gel UGN-101 resulted in a lengthy period of durable response when administered as induction treatment in patients with low-grade upper tract urothelial carcinoma.
Yoga Possesses Potential to Improve QoL, Immune Responses, and Inflammation in Prostate Cancer
September 13th 2021Improvements in quality of life, antitumor immune responses, and inflammation could be resulting benefits of the incorporation of regular yoga practice in the lives of men with prostate cancer who are undergoing prostatectomy.
MRgFUS Improved Sexual Function, Urinary Continence in Men with Intermediate-Risk Prostate Cancer
Magnetic resonance-guided focused ultrasound focal therapy delivered to the index lesion produced better outcomes for men with intermediate-risk prostate cancer compared with radical prostatectomy or radiation therapy.
Panvac Plus BCG Does Not Significantly Delay Recurrence in Advanced NMIBC
September 13th 2021The addition of a recombinant pox-viral vector vaccine Panvac™ to bacillus Calmette-Guérin did not significantly improve clinical outcomes for patients with BCG-unresponsive non–muscle invasive bladder cancer.
Masitinib Plus Docetaxel Produces PFS Benefit in mCRPC With Low Metastatic Involvement
September 13th 2021The investigational small molecule masitinib plus docetaxel resulted in a statistically significant 21% reduction in the risk of progression or death compared with placebo plus docetaxel in men with metastatic castration-resistant prostate cancer and baseline alkaline phosphatase levels of 250 IU/mL or less.
Systemic Review Underscores Need for Smoking Status Data on Genitourinary Cancer Trials
September 13th 2021Smoking status is not often reported on genitourinary cancer clinical trials, which limits understanding of how smoking impacts the treatment, survival, and quality of life of this patient population.
Darolutamide Delays Time to Deterioration in HRQoL Related to Urinary and Bowel Symptoms in nmCRPC
September 12th 2021Darolutamide was linked with a reduction in locally invasive procedures, delayed time to deterioration in health-related quality of life related to urinary and bowel symptoms in patients with nonmetastatic castration-resistant prostate cancer.
Enzalutamide/ADT Maintains Efficacy Regardless of Prior Antiandrogen Therapy in mHSPC
September 12th 2021Enzalutamide plus androgen-deprivation therapy produced clinical benefit over ADT alone in patients with metastatic hormone-sensitive prostate cancer, regardless of prior antiandrogen therapy and its pretreatment duration.
MSI-H/dMMR Prostate Cancer Linked With Response to Checkpoint Blockade
Patients with microsatellite instability–high or mismatch repair–deficient prostate cancer may be more likely to respond to treatment with checkpoint inhibitors compared with those who have high tumor mutational burden.
Prognostic Risk Group, Receipt of Subsequent Therapies May Impact OS in mCRPC Receiving Lutetium 177
Cancer and Leukemia Group B prognostic risk group and the receipt of subsequent FDA-approved life-prolonging therapies may impact overall survival in patients with metastatic castration-resistant prostate cancer who are receiving lutetium 177.
Nadofaragene Firadenovec Sustains Efficacy in Advanced NMIBC in Longer-Term Follow-Up
September 11th 2021Nadofaragene firadenovec, a novel intravesical gene therapy for patients with bacillus Calmette-Guérin unresponsive non–muscle invasive bladder cancer, demonstrated sustained durability according to findings from 2 cohorts of a phase 3 study.
Durvalumab/Vicineum Combo Shows Early Safety, Activity in High-Grade NMIBC
The combination of durvalumab and Vicineum was found to be well tolerated and to elicit complete responses in patients with Bacillus-Calmette Guérin–unresponsive non–muscle invasive bladder cancer.
Lutetium-PSMA Appears Safe in Locally Advanced High-Risk Prostate Cancer
Treatment with neoadjuvant lutetium prostate-specific membrane antigen followed by radical prostatectomy exhibited a favorable safety profile in patients with locally advanced high-risk prostate cancer.
TAR-200/Cetrelimab Under Investigation in Muscle-Invasive Bladder Cancer
TAR-200 plus cetrelimab may offer a superior treatment option for patients with muscle-invasive bladder cancer, and to answer this questions, investigators have initiated the randomized, phase 3 SunRISe-2 trial.
Nivolumab Plus Ipilimumab Response Signals Change for Cytoreductive Nephrectomy in Advanced RCC
September 11th 2021Primary tumor response to nivolumab plus ipilimumab observed results of a Japanese study indicates a changing role for the timing of cytoreductive nephrectomy for patients with advanced renal cell carcinoma.fr